Document is current
Any future updates will be listed below
-
Authors
Aflatooni, Shaliz
Dugan, Michelle M.
Boby, Aleena
Ghali, Helana
DePalo, Danielle K.
Naqvi, Syeda Mahrukh Hussnain
Mullinax, John E.
Zager, Jonathan S. https://orcid.org/0000-0002-6886-4468
- License Information
-
More Information
Article History
Received: 10 May 2024
Accepted: 23 August 2024
First Online: 10 September 2024
Disclosure
: Dr. Jonathan S. Zager has received payments from Delcath Systems–Medical Advisory Board. He has consulting agreements with Philogen, Merit Medical, Castle Biosciences, and Merck. His department receives research funding from Philogen, SWOG, Delcath Systems, and Provectus. Moffitt Cancer Center has licensed Intellectual Property (IP) related to the proliferation and expansion of tumor-infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. Dr. Mullinax (J.E.M.), an inventor of such intellectual property, participates in sponsored research agreements with Iovance Biotherapeutics, Intellia Therapeutics, and SQZ Biotech that are not related to this research, and has received research support not related to this research from NIH-NCI (K08CA252642), Ocala Royal Dames, and V Foundation. Dr. Mullinax has received ad hoc consulting fees from Merit Medical and Iovance Biotherapeutics. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Shaliz Aflatooni, Dr. Michelle M. Dugan, Aleena Boby, Helana Ghali, Dr. Danielle K. DePalo, and Dr. Syeda Mahrukh Hussnain Naqvi have no conflicts of interest.
